Gossamer Bio Inc. (GOSS) Announces $212M Private Placement Financing

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/16/2026

1. NVDA
2. CRWV
3. SPY
4. BAC
5. VRNS
6. FMC
7. RKLB
8. BLK
9. CAT
10. AA

Go back to Gossamer Bio Inc. (GOSS) Announces $212M Private Placement Financing

Gossamer Bio Announces $212 Million Private Placement Financing

July 20, 2023 7:56 AM EDT

- In Conjunction with Offering, Interim TORREY OLE Data and PROSERA Phase 3 Design Disclosed via 8-K; Conference Call to Discuss Data and Phase 3 Design with Leading PAH KOLs to be Held on July 25th -

SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement for gross proceeds... More